Corona Remedies IPO : All you Need to know
Corona Remedies IPO Details
The Corona Remedies IPO will open on 08 Dec 2025- 10 Dec 2025. The Total issue size of IPO is ₹655.37 cr. which includes a Entire IPO is OFS (Offer for sale).
- IPO Price Band: ₹1008-₹1062 Per Share
- Lot Size: 14 shares
- Minimum Investment (Retail): ₹14,112 – ₹14,868/-
- Allotment Date: 11 Dec 2025
- Listing Date: 15 Dec 2025 on NSE and BSE
| Details | Information |
| IPO Open Date | 08 Dec 2025 |
| IPO Close Date | 10 Dec 2025 |
| Price Band | ₹1008-₹1062 Per Share |
| Lot Size | 14 shares |
| Minimum Investment | ₹14,112 – ₹14,868/- |
| Issue Size | ₹655.37 cr. |
| Allotment Date | 11 Dec 2025 |
| Listing Date | 15 Dec 2025 on NSE and BSE |
| Corona Remedies IPO GMP | ₹290-300 (27%) |
Corona Remedies IPO GMP
As per market reports, the Corona Remedies IPO GMP is trading around ₹290 above issue price. This shows some positive demand before listing, but GMP can change quickly.
Corona Remedies IPO Issue Size
The Corona Remedies Ltd. IPO will open for subscription on 08 December 2025 to 10 December 2025. The Company wiill planning ₹655.37 cr through this public issue.
- Offer For Sale: ₹655.37cr. (61,71,101 shares ) existing shareholders will sell part of their stake, but the proceeds will not go to the company.,
Corona Remedies IPO Lot Size
Investors can apply for the IPO in lots. The Corona Remedies IPO Lot Size is fixed at 14 shares per lot.
Below is the table showing lot size details for Retail Investors and **HNIs (High Net Worth Individuals):
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Corona Remedies Ltd. IPO Prospectus
Corona Remedies Ltd. IPO Reservation
The IPO shares are divided among different investor categories. Here is the Corona Remedies IPO reservatimon (quota) details:
| Investor Category | Reservation % |
| QIB (Qualified Institutional Buyers) | 50% of the issue |
| NII / HNI (Non-Institutional Investors) | 15% of the issue |
| Retail Investors | 35% of the issue |
How to Apply for Corona Remedies Ltd. IPO
Applying for the Corona Remedies IPO is simple. You can apply through your demat account, net banking (ASBA), or brokerage app like Zerodha, Upstox, Groww, Angel One, ICICI Direct, etc.
Step-by-Step Guide
- Login to Your Demat Account
- Open your broker app (like Zerodha, Groww, Upstox) or net banking (like HDFC, ICICI, SBI).
- Go to IPO Section
- Look for the “IPO” tab or “Current Issues” option.
- Select
- Click on Corona Remedies Ltd. IPO Apply option.
- Choose Your Category & Lot Size
- Retail Investor: Minimum 1 lot = 14 shares.
- HNI (sHNI/bHNI): Higher multiples (check the Corona Remedies IPO lot size table above).
- Enter Bid Price
- You can bid at the cut-off price (safest option) or enter a price within the band ₹1008 – ₹1062
- Confirm & Submit
- Enter your UPI ID (if using UPI) and approve the mandate on your UPI app.
- For ASBA (net banking), the amount will be a blocked in your bank account.
- IPO closes on 10 December 2025.
- Allotment date: 11 December 2025.
- Check status on Bigshare services Pvt. Ltd.
Corona Remedies Ltd. Promotors Holding
- Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta
- Ankur Kirtikumar Mehta
| Description | Percentage (%) |
| Promoter Holding Pre-Issue | 72.50 |
| Promoter Holding Post-Issue | – |
Understanding IPO Lot Size, Price Band, and Allotment Process
What is IPO? A Beginner’s Guide to Initial Public Offerings in brief
Gold ETF vs Physical Gold – Which is the Smarter Investment?
Key Performance Indicators for Corona Remedies Ltd. IPO
| KPI | Value |
| Return on Capital Employed (ROCE) | 41.32% |
| EBITDA Margin | 20.55% |
| Price to Earning (P/E) Pre IPO | 43.47 |
| Return on Net Worth (RoNW) | 24.65% |
| PAT Margin (%) | 12.49% |
| Return On Equity (ROE) | 27.50% |
| Debt/Equity | 0.10 |
| Price to Book Value (P/BV) | 10.71 |
Corona Remedies Ltd. IPO Registrar and Lead Managers
Corona Remedies IPO Lead Managers.
- Pantomath Capital Advisors Pvt.Ltd
IDBI Capital Markets Services Ltd
Corona Remedies IPO Registrar
Bigshare Services Pvt Ltd
+91-22-6263 8200
Corona Remedies Ltd. Financial (in Crs)
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
About Corona Remedies Company
Corona Remedies Ltd is an Indian pharmaceutical company, incorporated in 2004.
The company is focused on developing, manufacturing and marketing pharmaceutical formulations — including tablets, capsules, syrups and other dosage forms — across various therapeutic segments.
Their therapeutic areas include women’s healthcare, cardio-diabetes (cardio + diabetic care), pain management, urology, along with multispecialty treatments, nutraceuticals, and other common medicines.
Manufacturing and Network
- Facilities: Corona Remedies operates multiple manufacturing facilities, including two key units in Gujarat (Bhayla) and Himachal Pradesh (Solan), which house production lines for complex drug manufacturing.
- Distribution: It boasts a pan-India marketing and distribution network, with a large and dedicated sales force (over 2,600 medical representatives) enabling deep penetration into various states and effective engagement with healthcare professionals.
- Product Portfolio: As of late 2024, the company’s product portfolio comprised over 67 brands across its therapeutic areas.
Corona Remedies
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059
+91 79 4023 3000
complianceofficer@coronaremedies.com
Stay Ahead with Busyshell.com
DISCLAIMER
The information provided on this website is strictly for educational and informational purposes only. We do not recommend any specific investments.
All content, including but not limited to articles, analysis, market updates, IPO information, stock recommendations, and financial data, should not be construed as personalized investment advice or solicitation to buy or sell any securities.
We are not SEBI registered advisors. This content is for informational and educational purposes only and should not be considered as investment advice.